Q-TWiST may help patients with advanced kidney cancer and their doctors weigh treatment options by focusing on quality of life, not just disease control.
Dr. Thomas Powles
Advertisement
Dr. Thomas Powles is a professor of Genitourinary Oncology, lead for Solid Tumour Research, and director of the Barts Cancer Centre at St. Bartholomew's Hospital, in London, England. He is also the co-lead of both the Barts Experimental Cancer Medicine Centre and the NIHR Biomedical Research Centre.
Articles by Dr. Thomas Powles
The landscape for patients with renal cell carcinoma could potentially change as the use of immune checkpoint inhibition shows promise for these patients.
Advertisement
Latest Updated Articles
Immune Checkpoint Inhibition Could Be the Future of Renal Cell Carcinoma TreatmentPublished: February 24th 2020 | Updated:
Advertisement
Advertisement
Trending on CURE
1
Peritoneal Mesothelioma Survivor Shares Ongoing Reality of Survivorship
2
What Does a Stage 2 Prostate Cancer Diagnosis Mean for Me?
3
SUNRiSE-1 Participant Shares Insights on Bladder Cancer Education
4
Becoming Cancer-Aware: How My Diagnosis Changed the Way My Family Sees Everyday Products
5
